FidoCure^® Veterinary Team Blog

As veterinarians, our work involves a wide range of emotions. We may experience the joy of treating a sick pet and seeing them recover, but we may also have to deliver the devastating news of a cancer diagnosis. It can be difficult to break such news to pet  parents who have a strong emotional bond with their dogs. However, as veterinary healthcare providers, it is our responsibility to help our clients through these tough times.

Canine cancer diagnoses can be devastating and demoralizing. While research and studies for human cancer have brought us a long way when it comes to treatment and instilling hope for our loved ones, the same can’t necessarily be said for the world of pet medicine. Despite this, there are many passionate veterinarians and vet oncologists out there who are helping to move the needle on pet cancer research and treatment. Taking cues from the progress made on human cancer treatment, FidoCure uses genomic testing to match dogs with targeted therapies for their specific cancer profile. Not only does this process increase the chances of a better prognosis, but it helps vets and vet oncologists deduce effective therapies for future canine cancer cases. FidoCure has already proven that a prognosis can be improved using targeted therapies. Take hemangiosarcoma for instance…

With a combination approach that included FidoCure® therapy, Pita lived for a year following a hemoabdomen and diagnosis of splenic hemangiosarcoma.

We were thrilled to see our recent Nature paper featured in last week's issue ofThe Cancer Letter! Our multi-year study has compared canine and human cancer journeys...

Sir Oliver, an 8 year old French Bulldog with TCC, is surviving and thriving thanks to his targeted therapeutic treatment4.5 months from FidoCure™ enrollment, Sir Oliver's latest CT scan showed a 38% reduction in his bladder tumor.

After one year of FidoCure®targeted therapy, Missy showed no evidence of pulmonary metastatic disease.

 

It is clear that the utilization of targeted therapy has proven beneficial in improving patient quality of life, extending survival time with minimal disease progression, and having an overall positive impact on patient care.

After six months of FidoCure® enabled therapy, Adley showed no evidence of pulmonary mass recurrence.

 

A 11 yr old Golden with hemophagocytic histiocytic sarcoma, 38 months in remission. FidoCure® identified a rare tumor suppressor mutation and suggested additional therapy that may have helped target tumor cells.

After more than 20 months of FidoCure® enabled treatment, Lulu has remained free from further metaseses. There has been no evidence of disease recurrence or pulmonary metastasis. Lulu has maintained a positive quality of life while in treatment and achieved extended time with her pet owners.